These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 17003382)

  • 1. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma.
    Schot BW; Zijlstra JM; Sluiter WJ; van Imhoff GW; Pruim J; Vaalburg W; Vellenga E
    Blood; 2007 Jan; 109(2):486-91. PubMed ID: 17003382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma.
    Derenzini E; Musuraca G; Fanti S; Stefoni V; Tani M; Alinari L; Venturini F; Gandolfi L; Baccarani M; Zinzani PL
    Cancer; 2008 Nov; 113(9):2496-503. PubMed ID: 18833583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
    Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
    Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma.
    Cremerius U; Fabry U; Wildberger JE; Zimny M; Reinartz P; Nowak B; Schaefer W; Buell U; Osieka R
    Bone Marrow Transplant; 2002 Jul; 30(2):103-11. PubMed ID: 12132049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.
    Spaepen K; Stroobants S; Dupont P; Vandenberghe P; Thomas J; de Groot T; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
    Ann Oncol; 2002 Sep; 13(9):1356-63. PubMed ID: 12196360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning.
    Kasamon YL; Wahl RL; Ziessman HA; Blackford AL; Goodman SN; Fidyk CA; Rogers KM; Bolaños-Meade J; Borowitz MJ; Ambinder RF; Jones RJ; Swinnen LJ
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):242-8. PubMed ID: 19167684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
    Qiao W; Zhao J; Wang C; Wang T; Xing Y
    Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT.
    Akhtar S; Al-Sugair AS; Abouzied M; Alkadhi Y; Dingle M; Abdelsalam M; Soudy H; Darwish A; Eltigani A; Elhassan TA; Nabil-Ahmed M; Maghfoor I
    Bone Marrow Transplant; 2013 Nov; 48(12):1530-6. PubMed ID: 23749108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of early 18F-fluoro-deoxyglucose positron emission tomography in chemosensitive relapsed lymphoma.
    Schot B; van Imhoff G; Pruim J; Sluiter W; Vaalburg W; Vellenga E
    Br J Haematol; 2003 Oct; 123(2):282-7. PubMed ID: 14531910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation.
    Smeltzer JP; Cashen AF; Zhang Q; Homb A; Dehdashti F; Abboud CN; Dipersio JF; Stockerl-Goldstein KE; Uy GL; Vij R; Westervelt P; Bartlett NL; Fehniger TA
    Biol Blood Marrow Transplant; 2011 Nov; 17(11):1646-52. PubMed ID: 21601641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.
    Moskowitz CH; Matasar MJ; Zelenetz AD; Nimer SD; Gerecitano J; Hamlin P; Horwitz S; Moskowitz AJ; Noy A; Palomba L; Perales MA; Portlock C; Straus D; Maragulia JC; Schoder H; Yahalom J
    Blood; 2012 Feb; 119(7):1665-70. PubMed ID: 22184409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.
    Querellou S; Valette F; Bodet-Milin C; Oudoux A; Carlier T; Harousseau JL; Chatal JF; Couturier O
    Ann Hematol; 2006 Nov; 85(11):759-67. PubMed ID: 16871391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.
    Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C
    Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.
    Hutchings M; Loft A; Hansen M; Pedersen LM; Buhl T; Jurlander J; Buus S; Keiding S; D'Amore F; Boesen AM; Berthelsen AK; Specht L
    Blood; 2006 Jan; 107(1):52-9. PubMed ID: 16150944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation.
    Crocchiolo R; Canevari C; Assanelli A; Lunghi F; Tassara M; Stanghellini ML; Clerici D; Landoni C; Servida P; Bernardi M; Peccatori J; Ferreri A; Gianolli L; Bordignon C; Caligaris-Cappio F; Ciceri F; Fazio F
    Leuk Lymphoma; 2008 Apr; 49(4):727-33. PubMed ID: 18398740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of early response assessment in lymphoma with FDG-PET.
    MacManus MP; Seymour JF; Hicks RJ
    Cancer Imaging; 2007; 7(1):10-8. PubMed ID: 17766210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
    Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
    J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis.
    Adams HJ; Kwee TC
    Ann Hematol; 2016 Apr; 95(5):695-706. PubMed ID: 26931115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up?
    Petrausch U; Samaras P; Veit-Haibach P; Tschopp A; Soyka JD; Knuth A; Hany TF; Mischo A; Renner C; Schaefer NG
    Ann Oncol; 2010 May; 21(5):1053-7. PubMed ID: 19914963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma.
    Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
    Haematologica; 2000 Jun; 85(6):613-8. PubMed ID: 10870118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.